Brief: Elicio Therapeutics Announces Preliminary Data From The Ongoing Amplify-7P Phase 1A Study Of Eli-002 7P In Patients With mKRAS-driven Solid Tumors
23/05/2024 23:54
May 23 (Reuters) - Elicio Therapeutics Inc ELTX.O :
* ELICIO THERAPEUTICS ANNOUNCES PRELIMINARY DATA FROM THE
ONGOING
AMPLIFY-7P PHASE 1A STUDY OF ELI-002 7P IN PATIENTS WITH
MKRAS-DRIVEN SOLID TUMORS AT THE 2024 ASCO ANNUAL MEETING
* ELICIO THERAPEUTICS INC: ELI-002 7P ADMINISTERED AS A
MONOTHERAPY WAS WELL TOLERATED
* ELICIO THERAPEUTICS: ELI-002 7P WAS WELL TOLERATED WITH T
CELL
RESPONSES CORRELATING WITH A REDUCTION IN TUMOR BIOMARKERS AT
RECOMMENDED PHASE 2 DOSE
Source text for Eikon: ID:nGNX8lyS2Z
Further company coverage: ELTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)